Company Overview of Adnexus Therapeutics, Inc.
Adnexus Therapeutics, Inc. discovers, develops, and distributes therapeutic class of biologics in the United States. The company’s product candidates include Angiocept/CT-322, an anti-angiogenesis agent for treating cancer that blocks the VEGFR-2 pathway; and other Adnectin therapies for the treatment of oncology, immunology, and cardiovascular diseases. Adnexus Therapeutics, Inc. was formerly known as Compound Therapeutics, Inc. and changed its name to Adnexus Therapeutics, Inc. in June, 2006. The company was founded in 2002 and is headquartered in Waltham, Massachusetts. As of October 19, 2007, Adnexus Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.
100 Beaver Street
Waltham, MA 02453
Founded in 2002
Key Executives for Adnexus Therapeutics, Inc.
Similar Private Companies By Industry
|Kuehnle Agrosystems, Inc.||United States|
|Arteriocyte, Inc.||United States|
|Evivrus, Inc.||United States|
|Toshiba Medical Research Institute USA, Inc.||United States|
|Scidera Genomics, LLC||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact Adnexus Therapeutics, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.